Therapeutic Application of Stem Cell and Gene Therapy in Parkinson’s Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pathology, Prevention and Therapeutics of Neurodegenerative Disease

• Publication date

  2018-09-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-981-13-0944-1_14
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Understanding Parkinson’s Disease through the Use of Cell Reprogramming

  2017cited by this paper
• Stem Cells for Modeling and Therapy of Parkinson's Disease

  2017cited by this paper
• The Threshold Theory for Parkinson's Disease.

  2017cited by this paper
• Induced dopaminergic neurons: A new promise for Parkinson’s disease

  2017cited by this paper
• Therapeutic Potential of Induced Neural Stem Cells for Parkinson’s Disease

  2017cited by this paper
• Development of stem cell-based therapies for Parkinson's disease

  2016cited by this paper
• Current and experimental treatments of Parkinson disease: A guide for neuroscientists

  2016cited by this paper
• Clinical translation of stem cell transplantation in Parkinson's disease

  2016cited by this paper
• Cell Therapy for Parkinson’s Disease

  2016cited by this paper
• Current advances in the generation of human iPS cells: implications in cell‐based regenerative medicine

  2016cited by this paper
• Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?

  2016cited by this paper
• Copy number variability in Parkinson’s disease: assembling the puzzle through a systems biology approach

  2016cited by this paper
• Towards a Better Treatment Option for Parkinson’s Disease: A Review of Adult Neurogenesis

  2016cited by this paper
• Treatment of Parkinson's disease using cell transplantation

  2015cited by this paper
• Parkinson's disease

  2015cited by this paper
• Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial

  2015cited by this paper
• Long-term health of dopaminergic neuron transplants in Parkinson's disease patients.

  2014cited by this paper
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

  2014cited by this paper
• Gene Therapy for the Nervous System: Challenges and New Strategies

  2014cited by this paper
• Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

  2014cited by this paper
• Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease

  2014cited by this paper
• Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions

  2014cited by this paper
• Review: The future of cell therapies and brain repair: Parkinson's disease leads the way

  2014cited by this paper
• Differential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin

  2014cited by this paper
• Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.

  2013cited by this paper
• Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques.

  2013cited by this paper
• Progress in Stem Cell Therapy for Major Human Neurological Disorders

  2013cited by this paper
• Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

  2013cited by this paper
• Mesenchymal stem cells and neuroregeneration in Parkinson's disease.

  2013cited by this paper
• Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens.

  2013cited by this paper
• Gene-based Therapies in Parkinson’s Disease

  2013cited by this paper
• Inducing translation

  2013cited by this paper
• Parkinson's Disease and Mesenchymal Stem Cells: Potential for Cell-Based Therapy

  2012cited by this paper
• Gene-based therapy of Parkinson’s Disease: Translation from animal model to human clinical trial employing convection enhanced delivery

  2012cited by this paper
• GABA Potency at GABAA Receptors Found in Synaptic and Extrasynaptic Zones

  2012cited by this paper
• Clonal Human Fetal Ventral Mesencephalic Dopaminergic Neuron Precursors for Cell Therapy Research

  2012cited by this paper
• Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease

  2012cited by this paper
• Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease

  2012cited by this paper
• Clinical translation of stem cells in neurodegenerative disorders.

  2012cited by this paper
• Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions.

  2012cited by this paper
• Neural stem/progenitor cells as promising candidates for regenerative therapy of the central nervous system

  2012cited by this paper
• The Adult Human Brain Harbors Multipotent Perivascular Mesenchymal Stem Cells

  2012cited by this paper
• Parkinson's disease: gene therapies.

  2012cited by this paper
• An Update on Gene Therapy in Parkinson’s Disease

  2011cited by this paper
• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

  2011cited by this paper
• Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD

  2011cited by this paper
• In Vitro and in Vivo Enhanced Generation of Human A9 Dopamine Neurons from Neural Stem Cells by Bcl-XL*

  2010cited by this paper
• Gene Therapy in Parkinson’s Disease

  2010cited by this paper
• Mesenchymal stem cells for the treatment of neurodegenerative disease.

  2010cited by this paper
• Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease

  2010cited by this paper
• A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

  2010cited by this paper
• Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice

  2010cited by this paper
• Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

  2010cited by this paper
• Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

  2010cited by this paper
• Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.

  2009cited by this paper
• Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

  2009cited by this paper
• Regionally Specified Human Neural Progenitor Cells Derived from the Mesencephalon and Forebrain Undergo Increased Neurogenesis Following Overexpression of ASCL1

  2009cited by this paper
• Therapeutic Microinjection of Autologous Adult Human Neural Stem Cells and Differentiated Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome

  2009cited by this paper
• Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti‐inflammatory action

  2009cited by this paper
• Generation and properties of a new human ventral mesencephalic neural stem cell line.

  2009cited by this paper
• HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts

  2008cited by this paper
• Transplanted dopaminergic neurons develop PD pathologic changes: A second case report

  2008cited by this paper
• Mesenchymal stem cells as mediators of neural differentiation.

  2008cited by this paper
• Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism

  2007cited by this paper
• Dopamine neuron systems in the brain: an update.

  2007cited by this paper
• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

  2007cited by this paper
• Generation of human cortical neurons from a new immortal fetal neural stem cell line.

  2007cited by this paper
• Patient-Specific Stem Cell Lines Derived from Human Parthenogenetic Blastocysts

  2007cited by this paper
• Point source concentration of GDNF may explain failure of phase II clinical trial.

  2006cited by this paper
• Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

  2006cited by this paper
• Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

  2006cited by this paper
• Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models

  2005cited by this paper
• The subthalamic nucleus in the context of movement disorders.

  2004cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

  2003cited by this paper
• Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease.

  2002cited by this paper
• Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model

  2002cited by this paper
• Human adipose tissue is a source of multipotent stem cells.

  2002cited by this paper
• Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo.

  2000cited by this paper
• Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

  1999cited by this paper
• Embryonic stem cell lines derived from human blastocysts.

  1998cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper

• The ameliorating effects of adipose-derived stromal vascular fraction cells on blue light-induced rat retinal injury via modulation of TLR4 signaling, apoptosis, and glial cell activity

  2024cites this paper
• Drug reprofiling history and potential therapies against Parkinson’s disease

  2022cites this paper
• Comparative study between bone marrow mesenchymal stem cell and their conditioned medium in the treatment of rat model of Parkinsonism

  2020cites this paper
• Method for Evaluating Neuromodulatory Properties of Dental Pulp Stem Cell as an In Vitro Model for Parkinson's Disease.

  2019cites this paper